It would be interesting to explore whether in vivo administration of Mek1/2 inhibitors alleviates neutropenia in Gfi1−/− mice; if it does, suppression of Erk1/2 signaling could represent a novel therapeutic approach in the treatment of SCN patients with GFI1 mutations. This evidence concerns the gene MAPK3 and severe congenital neutropenia.